AZITHROMYCIN, ERYTHROMYCIN AND CLOXACILLIN IN THE TREATMENT OF INFECTIONS OF SKIN AND ASSOCIATED SOFT-TISSUES
AZITHROMYCIN, ERYTHROMYCIN AND CLOXACILLIN IN THE TREATMENT OF INFECTIONS OF SKIN AND ASSOCIATED SOFT-TISSUES
复制标题
DOI：
10.1177/030006059101900602
复制
发表时间：
1991-11-01
影响因子：
1.6
通讯作者：
WEIGL, H
中科院分区：
文献类型：
--
作者：
DANIEL, R;AUSTAD, J;WEIGL, H
Azithromycin (total dose 1.5 g) given orally in rive or six doses over 5 days was compared with erythromycin and cloxacillin both given orally as 500 mg four times daily for 7 days in two multicentre studies of patients with skin and associated soft-tissue infections. Azithromycin eradicated baseline pathogen(s), mainly Staphylococcus aureus, in 89% compared with in 78%, of erythromycin-treated patients (P = 0.501) and in 78% compared with in 59% of cloxacillin-treated patients (P = 0.421). No statistically significant difference in clinical cure was reported between azithromycin (74%) and erythromycin (75%, P = 1.00) and between azithromycin (60%) and cloxacillin (47%, P = 0.301) treatment groups. The side-effects reported for azithromycin were mainly mild or moderate gastro-intestinal complaints and there were no major abnormalities in laboratory parameters. It is concluded that azith-romycin was as effective as, but better tolerated than, either erythromycin or cloxacillin and short-course therapy may improve patient compliance.
